Kornimate/medical-research-clean huggingface dataset:
an epidemiological survey of cancer-related fatigue among taiwanese gynecologic cancer patients

Conditions: Fatigue

Summary: this study aim is to examine the prevalence, severity, and management of crf among taiwanese gynecologic cancer patients.

the cross-sectional survey is conducted at oncology inpatients unit and outpatients clinics of hospitals in taiwan. furthermore, the results will elucidate not only the epidemiology of crf in taiwan, but will supply physicians with more understanding about crf, and help them to enhance the quality on cancer care to being perfected in the future.

Eligibility criteria:
inclusion criteria: * patients who signed the informed consent form * the age of eligible patients should be ≥ 20 years old. * inpatients or outpatients who have been given a diagnosis of gynecologic cancer. * able to communicate verbally and completely fill out the questionnaires exclusion criteria: * patients who have been given a diagnosis of cognitive impairment are unable to complete the questionnaires
can a smartphone listen to your heart? a performance study on detecting abnormalities in your heart sounds

Conditions: Valvular Heart Disease; Heart Murmurs; Cardiovascular Abnormalities

Summary: this observational study aims to assess the performance of the software called ausculto™. ausculto™ is a collection of computer algorithms that intend to analyse heart sounds recorded from the built-in microphone of a smartphone for abnormal sounds. participants will have their heart sounds recorded during their regular clinic appointment after consenting to participate in this study. researchers will manually annotate the recorded heart sounds to create a database for use in future training and testing of artificial intelligence (ai) intended for medical uses.


Eligibility criteria:
inclusion criteria: * age: ≥22 years (adult) * outpatients who have undergone echocardiography within 3 years at their normal non-research follow-up clinic visit appointment exclusion criterion: * implanted active medical devices in the torso, such as pacemakers and defibrillators

Keywords: auscultation smartphone heart sounds heart auscultation phonocardiography stethoscopes telemedicine
parent training for attention deficit hyperactivity disorder (adhd) preschoolers

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this research is to evaluate and compare the effectiveness of two parenting programs in reducing the adhd symptoms and behavioral problems of preschool children with adhd through a controlled study. one program is a home-based parent training intervention that is designed to enhance the parent-child interaction, constructive parenting skills, and the child's tolerance for delay. the other intervention is a clinic-based parent training program that focuses on reducing noncompliance in preschool children and improving parenting skills. both programs consist of private weekly parenting sessions with clinical psychologists - once a week for 8 weeks. the sessions are 1-1.5 hours in length. both programs use behavior modification as a means of improving oppositional and non-compliant child behavior. both interventions also involve procedures that focus on improving children's attention. neither program involves medication, and all families will receive one of the two parenting programs being evaluated. study evaluations, as well as participation in the parenting programs, are provided at no cost to families. evaluation and parenting sessions can be scheduled at times convenient to families.


Eligibility criteria:
inclusion criteria: * age = 3.0 - 4.11 * in preschool program at least 2 half days per week * meets criteria for adhd on clinical evaluation / disc * adhd severity: \> 1.5 sd above mean for age/sex on ctrs-r * adhd severity: \> 1.0 sd above mean for age/sex on cprs-r exclusion criteria: * current medication treatment for adhd * iq \< 70 (full scale on wppsi iii) * pervasive developmental disorder * psychosis * severe receptive language impairment * neurological disorder * significant medical disorder * primary caretaker is not able to participate * non-english speaking primary care taker

Keywords: attention behavior problems compliance evaluation preschool adhd overactive inattentive attention deficit hyperactivity disorder in preschoolers
clinical study to investigate the efficacy and safety of wilate during prophylaxis in previously treated patients with vwd

Conditions: Von Willebrand Diseases

Summary: this is a prospective, non-controlled, international, multi-center phase 3 study investigating the efficacy and safety of wilate in previously treated adult patients with vwd, to obtain additional data on the safety and efficacy of wilate in previously treated patients with vwd undergoing regular prophylaxis.


Eligibility criteria:
inclusion criteria: patients who meet all of the following criteria are eligible for the study: * aged ≥6 years at the time of screening * vwd type 1 (baseline von willebrand factor activity \[vwf:ristocetin co-factor (rco)\] \<30 iu/dl, 2a, 2b, 2m, or 3 according to medical history requiring substitution therapy with a vwf-containing product to control bleeding * currently receiving on-demand treatment with a vwf-containing product with at least 1, and an average of ≥2, documented spontaneous bes per month in the last 6 months, with at least 2 of these bes requiring treatment with a vwf-containing product * availability of records to reliably evaluate type, frequency, and treatment of bes for at least 6 months of on-demand treatment before screening * female patients of child-bearing potential must have a negative urine pregnancy test at screening and agree to use adequate birth control measures; in case hormonal contra-ception is used, the medication class should remain unchanged for the duration of the study * all patients to provide voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted exclusion criteria: patients who meet any of the following criteria are not eligible for the study: * having received on-demand or prophylactic treatment with a vwf-containing product but having no records available to reliably evaluate the type, frequency, and treatment of bes over a period of at least 6 months of on-demand treatment * history, or current suspicion, of vwf or fviii inhibitors * medical history of a thromboembolic event within 1 year before enrolment * severe liver or kidney diseases (alanine aminotransferase \[alat\] and aspartate trans-aminase \[asat\] levels \>5 times of upper limit of normal, creatinine \>120 µmol/l) * platelet count \<100,000/µl at screening (except for vwd type 2b) * body weight \<20 kg at screening * patients receiving, or scheduled to receive, immunosuppressant drugs (other than an-tiretroviral chemotherapy), such as prednisone (equivalent to \>10 mg/day), or similar drugs * pregnant or breast-feeding at the time of enrolment * cervical or uterine conditions causing abnormal uterine bleeding (including infection, dysplasia) * treatment with any imp in another interventional clinical study currently or within 4 weeks before enrolment * other coagulation disorders or bleeding disorders due to anatomical reasons * known hypersensitivity to any of the components of the study drug
stevia rebaudiana bertoni on levels of gcf glucose and bio-markers in diabetics.

Conditions: Periodontitis

Summary: with the increase in the incidence of diabetes and obesity, among other artificial sweeteners the need of natural non-caloric sweetener with acceptable taste and without any adverse effects is demanding.so,the use of stevia presents beneficial effects to general and oral health and its properties could result potentially effective in the treatment of periodontal diseases.

stevia is considered as a novel molecule, because it is 100% natural and non caloric sweetener, with more sweetness than sucrose, without any adverse effects. it also demonstrates multiple benefits like anti-plaque effect, anti-diabetic effect, anti-periodontophatics properties, anti-hypertensive properties, anti-cariogenic properties etc. there are many studies conducted on stevia in humans, which justifies my study.

Eligibility criteria:
inclusion criteria: * subjects that will be included in the study are in the age group ranging from 20-70 years -with established diabetes and under medication to maintain normal glycemic state i.e;hb1ac \< 7％. * oral findings including the presence of minimum of 16 natural teeth with minimum of 4 nonadjacent sites showing pocket depths≥ 5 mm. exclusion criteria: subjects will be excluded from the study if they are using * any type of mouth-rinses or if they had underwent any periodontal therapy within the 3-months of the study or * if they were under antibiotics within the 3-months of the study.

Keywords: biomarkers gingival crevicular fluid glucose diabetes
lifestyle intervention in overweight women

Conditions: Obesity; Weight Loss; Lifestyle, Sedentary; Physical Activity; Nutritional and Metabolic Disease; Behavior, Health; Cardiovascular Risk Factor

Summary: the exercise and obesity health promotion (peso) program is a randomized controlled trial designed to analyze the effects of a lifestyle intervention in weight management and health-related parameters of overweight and obese premenopausal women

the peso (exercise and obesity health promotion program) is a program of weight control and exercise promotion for overweight and obese premenopausal women, developed by specialists in exercise, nutrition, and psychology, under medical supervision. it is a program that promotes the autonomy of the participants and the permanent modification of their habits and lifestyles, without the use of drugs or any other products, devices, or techniques of "slimming". participants in the peso program were able to enjoy a regular and multifaceted group program, aiming to increase knowledge about permanent body weight control, increased motivation and practice of physical activity and exercise, and improved habits food and nutrition. increases in functional mobility, metabolic health, quality of life and the physical and mental well-being of the participants are central priorities of this program. the peso program was conducted in a university context and was led by teachers and researchers from the faculty of human motors and other national and foreign institutions. the program is not for commercial purposes, it does not entail financial costs for the participants and it is involved in a wide range of scientific research projects, which have been recognized by individuals and external entities as relevant and of interest to the general population and the community in particular.

Eligibility criteria:
inclusion criteria: * older than 24 years, * be premenopausal and not currently pregnant, * bmi higher than 24.9 kg/m2, * free from major disease exclusion criteria: * not meeting the inclusion criteria

Keywords: obesity body composition weight management cardiovascular and metabolic markers behavioral change exercise
evaluation of extended tear film break up time (tfbut) with an ocular emulsion

Conditions: Dry Eye

Summary: the primary objective of this investigation will be to quantify the increase in tear film break-up time (tfbut) associated with the instillation of a single eyedrop of an ocular emulsion in dry eye sufferers.

the secondary objective of this investigation will be to compare the tear film break up time measured with two different techniques.

Eligibility criteria:
inclusion criteria: 1. the subject must be 18 years of age or older; 2. the subject must have a best corrected visual acuity of 0.6 logmar (\~6/24) or better in each eye 3. the subject must not have used any topical ocular drops for approximately 24 hours prior to the enrolment/screening visit 4. the subject must be classified as dry eye at enrolment/screening visit according to the following criteria: * subjects' self-assessment of dry eye status (answer of at least "some of the time" to the question, "how often have your eyes felt dry enough to want to use eye drops?"); * tfbut measured with det ≤ 5 seconds in at least one eye; * grade 1 for meibomian gland expression in both eyes; * evidence of missing meibomian glands in both eyes. exclusion criteria: 1. history or evidence of ocular or intraocular surgery in either eye within the past six months. 2. history or evidence of serious ocular trauma in either eye within the past six months. 3. current punctal occlusion of any type (e.g., collagen plugs, silicone plugs). 4. history or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye. 5. use of any concomitant topical ocular medications during the study period. 6. ocular conditions such as conjunctival infections, iritis, or any other ocular condition that may preclude the safe administration of either drop under investigation. 7. participation in an investigational drug or device study within 30 days of entering this study.

Keywords: ocular emulsion optive™ lubricant tear film break up time
corneal ulcer prevention through health education

Conditions: Corneal Ulcer

Summary: a community-randomized trial comparing villages randomized to receive an intervention consisting of a trained community health volunteer who brings patients to the nearest vision centers or primary health care centers for treatment after diagnosing a corneal abrasion to control villages receiving no additional intervention. the primary outcome of corneal ulcer will be measured by baseline and annual population-based census performed in both intervention and control villages by masked examiners from baseline to 24 months. each resident in the village will be asked about their ocular history and, if suspected of having a corneal ulcer, will be examined for evidence of a corneal opacity. annual visits will occur, coinciding with the end of the harvest season. in villages randomized to intervention, an active promotion campaign will be undertaken to urge residents to notify the village eye health worker within 24 hours of ocular trauma. in control villages, abrasions and ulcers will be treated if they present to a clinic or are found during the annual monitoring visits, but active promotion of corneal abrasion care will not be offered.

research question: can the investigators prevent corneal ulcers on a mass scale? aim 1: to determine whether diagnosis and prophylaxis of corneal abrasions by village health workers will reduce the incidence of corneal ulceration in rural south india. the investigators hypothesize that communities in which village eye health workers are available to diagnose and prophylax corneal abrasions will have a significantly lower incidence of corneal ulceration compared to communities without this service. aim 2: to determine the cost-effectiveness of a village eye worker program to prevent corneal ulcers. the investigators hypothesize that preventing corneal ulcers through a village eye worker program will be more cost-effective than the current standard of treating corneal ulcers after patients present at health care facilities. aim 3: to determine the incidence of corneal ulceration in this south indian population. the investigators anticipate that the incidence of ulcers is lower than estimated in our 1995 incidence survey, but still far higher than that observed in the developed world.

Eligibility criteria:
inclusion criteria: * presence of a corneal abrasion * willingness to be treated with topical antibiotic and antifungal ointments 3 times a day for 3 days * appropriate consent exclusion criteria: * evidence of a corneal ulcer * evidence of other acute eye disease requiring urgent care * known allergy to study medications * not willing to participate
evaluation of mn-166 (ibudilast) for 12 months followed by an open-label extension for 6 months in patients with als

Conditions: Amyotrophic Lateral Sclerosis

Summary: a phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of mn-166 given to als participants for 12 months followed by a 6-month open-label extension phase.

this is a phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of mn-166 followed by an open-label extension phase compared to matching placebo in subjects diagnosed with als. the study will consist of a screening phase (up to 30 days) followed by a double-blind phase (12 months). following the screening phase, subjects who continue to meet entry criteria will be randomly assigned to one of two treatment groups: mn-166 or matching placebo in a 1:1 ratio. upon completion of the double-blind phase, subjects will be given the option to continue to the open-label extension phase for a period of six months.

Eligibility criteria:
major inclusion criteria: * male or female subjects age 18 - 80 years, inclusive; * diagnosis of familial or sporadic als as defined by the el escorial-revised (2000) research diagnostic criteria for als \[clinically definite, clinically probable, probable-laboratory-supported\]; * als onset of ≤18 months from first clinical signs of weakness prior to screening; * if currently using riluzole, subject must be on a stable dose for at least 30 days prior to initiation of study drug; * if currently using edaravone, subject should have completed at least 14 days of their initial treatment cycle prior to initiation of study drug; * last documented pulmonary function test result (i.e., slow vital capacity or forced vital capacity) must be greater than or equal to 70% predicted; * able to swallow study medication capsules; * no known allergies to the study drug or its excipients; * received pneumococcal vaccine within 6 years prior to starting clinical trial. major exclusion criteria: * confirmed hepatic insufficiency or abnormal liver function (ast and/or alt \>3 times upper limit of normal); * currently diagnosed with a clinically significant psychiatric disorder or dementia that would preclude evaluation of symptoms; * currently use or treated with parenteral (intramuscular or intravenous) high dose (\>25 mg/week) vitamin b12 within 30 days prior to study drug administration; * poor peripheral venous access that will limit the ability to draw blood as judged by the investigator; * currently participating, or has participated in a study with an investigational or marketed compound or device within 30 days or 5 half-lives, whichever is shorter, prior to signing the informed consent; * use of tracheostomy or \>22/24-hour ventilatory support.

Keywords: als mn-166 ibudilast amyotrophic lateral sclerosis
risk factors for pediatric emergence agitation and analysis of serum or urine metabonomics in children with agitation

Conditions: Emergence Agitation; Pain; Metabolomics

Summary: it is known that some factors are associated with emergence agitation(ea), and investigators are still unable to predict accurately those who undergoing maxillofacial surgery are at great risks.this study intend to identify the risk factors for ea and to explore the mechanism of ea , which is helpful for early prediction, prevention and treatment in children.

this study was divided into two parts. the first part, multivariate regression analysis were conducted to identify the risk factors for pain and ea following maxillofacial surgery in children. the second part, metabolomics research was used to explore the relationship between metabolites and ea in children.

Eligibility criteria:
eligibility criteria in part i inclusion criteria: 1. patients undergoing palatopharyngoplasty/tonsillar and/or adenoidectomy, auricle reconstruction, and photodynamic therapy for vascular malformations on face. 2. aged between 3 years and 12 years. 3. american society of anesthesiologists(asa) class i-ii. exclusion criteria: 1. patients with developmental delays. 2. patients with mental disorders. 3. patients with severe liver and kidney damage,or other heart and lung disease. 4. reject to participate in the trials. eligibility criteria in part ii inclusion criteria: 1. patients who underwent adenoidectomy or adenotonsillectomy in part i of this study. 2. aged between 3 years and 7 years. 3. american society of anesthesiologists(asa) class i-ii. 4. patients who underwent sevoflurane anesthesia maintainance. exclusion criteria: 1. patients with developmental delays or mental disorders. 2. patients with neurological or psychiatric diseases. 3. patients with severe liver and kidney damage,or other heart and lung disease. 4. patients with metabolic diseases or family inherited diseases. 5. patients who received drug treatment or intravenous nutritional supports.

Keywords: pediatric emergence agitation postoperative pain metabolomics
mesenchymal stromal cells for the treatment of patients with covid-19.

Conditions: COVID-19 Pneumonia; COVID-19

Summary: the purpose of this study is evaluate the feasibility, safety and potential efficacy of an advanced cell therapy product for the treatment of patients with sars-cov-2 pneumonia.

forty patients with covid-19 will receive an intravenous infusion of one dose of 1.000.000 umbilical cord mesenchymal cells per kilo of the patient. twenty patients will receive a placebo (ringer's lactate solution, albumin and heparin). conventional treatment will be performed together with the infusion of cells, during the study period. the evaluation times will be at pre-infusion, 6 and 24 hours, days 5 and 28, 3 and 6 months. the patient exams performed: serology, biochemistry, blood count and blood gas analysis, metabolomics/proteomics, antibody evaluation, electrocardiogram, ct-scan and x-ray, cytokines, viral load, cytometry, and clinical evaluation. the patients will be evaluated all the time, during hospitalization period, to assess adverse events.

Eligibility criteria:
inclusion criteria: * both sexes; * aged 18 to 79 years old; * hospitalized patients; * radiological diagnosis of viral pneumonia; * virological diagnosis of sars-cov-2 infection; * with noninvasive ventilatory support; * c-reactive protein and ferritin above the reference value considered normal; * assent confirmed to participate in the study. exclusion criteria: * contraindications for use of corticosteroids; * immunosuppressive, cytotoxic and antiviral treatment, experimental medications and chronic corticosteroid use; * morbid obesity (bmi\> 35); * multiple organ dysfunction syndrome; * pre-malignant neoplastic conditions with life expectancy lower than 1 year old; * pre-existing chronic illnesses like chronic dialysis kidney disease, chronic liver disease, congestive heart failure class iv; pulmonary hypertension (who class iii/iv); * pre-existing or current thromboembolic pathology; * transplanted patients; * pre-existing severe allergic reaction; * history of hiv and tuberculosis; * enrollment in another clinical trial; * pregnancy or breastfeeding.
safety and efficacy of gaseous nitric oxide on venous stasis leg ulcers

Conditions: Venous Ulcers

Summary: this study will test the safety and efficacy of nitric oxide gas in the treatment of venous leg ulcers

prospective, single center. controlled study of a moisture retentive wound dressing and sustained compression with 6 weeks of 8 hour daily nitric oxide treatments.

Eligibility criteria:
inclusion criteria: * must have a venous stasis ulcer between the knee and the ankle. * ulcer duration must be 60 days or greater exclusion criteria: * has an ulcer that is deemed by the investigator to be caused primarily by a medical condition other than venous insufficiency * suffers from diabetes mellitus with hba1c ≥ 8% * suffers from clinically significant arterial disease * is pregnant, a nursing mother or a woman of child bearing potential who is not using an adequate form of contraception (or abstinent) the above is a partial list of the inclusion and exclusion criteria; however, other inclusion and exclusion criteria may apply.

Keywords: nitric oxide venous leg ulcers